{Reference Type}: Journal Article
{Title}: Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.
{Author}: Hamacher R;Lanzafame H;Mavroeidi IA;Pabst KM;Kessler L;Cheung PF;Bauer S;Herrmann K;Schildhaus HU;Siveke JT;Fendler WP;
{Journal}: PET Clin
{Volume}: 18
{Issue}: 3
{Year}: 2023 Jul
暂无{DOI}: 10.1016/j.cpet.2023.02.008
{Abstract}: The theranostic use of fibroblast activation protein inhibitors (FAPIs) is a novel approach in oncology. Sarcomas are a heterogenous group of rare malignant tumors. Prognosis remains poor in advanced/metastatic disease due to limited therapeutic options. Sarcoma frequently demonstrate high expression of fibroblast activation protein alpha on the tumor cells themselves, in contrast to other solid tumors, where it is mainly expressed on cancer-associated fibroblasts. Consequently, high in vivo uptake of FAPI in PET is observed in sarcoma. Moreover, retrospective case reports and series demonstrated feasibility of FAPI radioligand therapy with signs of tumor response.